

Marquette Intellectual Property Law Review

Volume 18 | Issue 1

Article 20

IP Policy Forum: Foreword From the Editors

Follow this and additional works at: <http://scholarship.law.marquette.edu/iplr>



Part of the [Intellectual Property Commons](#)

Repository Citation

IP Policy Forum: Foreword From the Editors, 18 Marq. Intellectual Property L. Rev. 11 (2014).

Available at: <http://scholarship.law.marquette.edu/iplr/vol18/iss1/20>

This Prefatory Matter is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. It has been accepted for inclusion in Marquette Intellectual Property Law Review by an authorized administrator of Marquette Law Scholarly Commons. For more information, please contact megan.obrien@marquette.edu.

INTELLECTUAL PROPERTY POLICY FORUM

PHARMACEUTICAL DEVELOPMENT AND HEALTHCARE INNOVATION

FOREWORD FROM THE EDITORS	13
TOMMY THOMPSON, <i>Drug Development – Translating Basic Research into New Medicines – and this Issue of IPLR</i>	15
G. STEVEN BURRILL, <i>Forward-looking View of Healthcare Innovation, from a Leading Life Science Venture Capitalist</i>	17
DAVID MEININGER, <i>The Increasing Importance of Biologics-based Drugs in Pharmaceutical Pipelines</i>	19
GARRET A. FITZGERALD, <i>Need for New IP Approaches to Facilitate Collaborative (Academic-Industrial) Drug Development</i>	21
BRUCE BLOOM, <i>New Business Models to Find Cures and Lower Healthcare Costs: A Role for Drug Repurposing</i>	23
RAMAIAH MUTHYALA, <i>Repurposing & Collaborative Drug Development for Rare Diseases</i>	25
HARSHA K. RAJASIMHA, <i>The Future of Clinical Trials: More Transparency and Pharmacogenomics</i>	27
JOHN R. RAYMOND, <i>Implications of Genomics Advances for Drug Discovery, Clinical Therapies, & Rare Disease Research</i>	29
HUGH LAVERTY & MAGALI POINOT, <i>Intellectual Property Rights (IPR) in Collaborative Drug Development in the EU: Helping a European Public-Private Partnership Deliver – the Need for a Flexible Approach to IPR</i>	31

FOREWORD FROM THE EDITORS

In this issue of the Marquette Intellectual Property Law Review (IPLR), we have decided to experiment with some new concepts. First, this issue is thematic, with a majority of articles and comments focusing on *Pharmaceutical Development and Healthcare Innovation*. We felt that having an occasional thematic issue would be of value for readers with interest in a topical area, and also increase the overall impact of legal scholarship in the field, towards the goal of furthering public policy discussions. That brings us to our second innovation, which is something we refer to as our *Intellectual Property Policy Forum*. The purpose of this section, which is on the pages that follow, is to solicit forward-looking views on the topical issue, from thought leaders in the field. To this end, we have identified an impressive array of nine leading figures in the area of *Pharmaceutical Development and Healthcare Innovation*. Their views and commentary give a view to where this field may be headed, and also gives a broader perspective to the legal scholarship contained in this topical issue. Finally, to personalize this public policy and legal dialog, we have provided brief biographical information and pictures of our various contributors.

On behalf of the editorial board and staff of the Marquette IPLR, we hope you enjoy—and continue yourself—this dialog at the interface of law and public policy, on the topic of *Pharmaceutical Development and Healthcare Innovation*.

THE MARQUETTE INTELLECTUAL PROPERTY
LAW REVIEW EDITORIAL BOARD